Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001172661-25-002196
Filing Date
2025-05-15
Accepted
2025-05-15 15:03:10
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9059
  Complete submission text file 0001172661-25-002196.txt   11170
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Subject) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90268 | Film No.: 25951720
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 CLARENDON STREET 52ND FLOOR BOSTON MA 02116
Business Address 200 CLARENDON STREET 52ND FLOOR BOSTON MA 02116 857-702-0388
Cormorant Asset Management, LP (Filed by) CIK: 0001583977 (see all company filings)

EIN.: 462108927 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A